Early intervention, relapse prevention, and neuroprogression in bipolar disorder: The evidence matters
Bipolar Disorders · 2024-06 · 26 (4) · 313-316
DOI: 10.1111/bdi.13435 ↗Kurz gefasst
Editorial in der Zeitschrift Bipolar Disorders, online erschienen am 25.04.2024. Verfasst von Lakshmi N Yatham und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Bipolar Disorder, Secondary Prevention, Disease Progression. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Yatham LN: reports consultant/speaker fees from Alkermes, Allergan (currently Abbvie) Dainippon Sumitomo Pharma, Gedeon Richter, GSK, Intracellular Therapies, Merck, Sanofi, and Sunovion, and grants from Allergan (now AbbVie), CIHR, and Dainippon Sumitomo, outside the submitted work, over the last 3 years. Schaffer A has received consultant/speaker fees from Allergan/Abbvie, GSK, Lundbeck, Otsuka in the past 3 years. Kessing LV has been a consultant for Teva and Lundbec during the last 3 years. Miskowiak KW reports consultancy fees from Lundbeck, Angelini, Gedeon Richter, and Janssen-Cilag in the past 3 years. Kapczinski F received grants or participated in the board or as speaker for the following entities: Johnson & Johnson, Daiichi Sankyo, Ache, and Janssen. Vieta E has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, AbbVie, Adamed, Angelini, Biogen, Biohaven, Boehringer-Ingelheim, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, HMNC, Idorsia, Johnson & Johnson, Lundbeck, Medincell, Merck, Newron, Novartis, Orion Corporation, Organon, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, and Viatris, outside the submitted work. Post RM: Speaker for Sunovion and Abbvie. Berk M: Grant/Research Support: MRFF, NHMRC, Congressionally Directed Medical Research Programs (CDMRP) USA, AEDRTC Australian Eating Disorders Research and Translation Centre, Patient-Centered Outcomes Research Institute (PCORI), Baszucki Brain Research Fund, Danmarks Frie Forskningsfond. Psykiatrisk Center Kobenhavn, Stanley Medical Research Institute, Victorian Government Department of Jobs, Precincts and Regions, Wellcome Trust, Victorian Medical Research Acceleration Fund, Controversias Psiquiatria Barcelona, CRE, Victorian COVID-19 Research Fund, Consultancies: Lundbeck, Sandoz, Servier, Medisquire, HealthEd, ANZJP, EPA, Janssen, Medplan, RANZCP, Abbott India, ASCP, International Society of Bipolar Disorder, Precision Psychiatry, Penn State College of Medicine, Shanghai Mental Health Centre. (Last 3 years)—all unrelated to this work. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
- Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
- Copenhagen Affective disorder Research Center (CADIC), Psychiatric Center Copenhagen, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Neurocognition and Emotion in Affective Disorders (NEAD) Centre, University of Copenhagen, Copenhagen, Denmark.
- Department of Psychology, and Mental Health Services, Capital Region of Denmark Psychiatric Centre Copenhagen, Frederiksberg Hospital, Frederiksberg, Denmark.
- Federal University - UFRGS, Porto Alegre, Brazil.
ORCID-Profile: Lakshmi N Yatham, Ayal Schaffer, Lars V Kessing, Flavio Kapczinski, Eduard Vieta, Robert M Post
Zitieren
APA
Yatham, L. N., Schaffer, A., Kessing, L. V., Miskowiak, K., Kapczinski, F., Vieta, E., Post, R. M., & Berk, M. (2024). Early intervention, relapse prevention, and neuroprogression in bipolar disorder: The evidence matters. Bipolar Disorders, 26(4), 313-316. https://doi.org/10.1111/bdi.13435
Vancouver
Yatham LN, Schaffer A, Kessing LV, Miskowiak K, Kapczinski F, Vieta E, et al. Early intervention, relapse prevention, and neuroprogression in bipolar disorder: The evidence matters. Bipolar Disorders. 2024;26(4):313-316. doi:10.1111/bdi.13435
BibTeX
@article{Yatham2024,
author = {Yatham, Lakshmi N and Schaffer, Ayal and Kessing, Lars V and Miskowiak, Kamilla and Kapczinski, Flavio and Vieta, Eduard and Post, Robert M and Berk, Michael},
title = {Early intervention, relapse prevention, and neuroprogression in bipolar disorder: The evidence matters},
journal = {Bipolar Disorders},
year = {2024},
volume = {26},
number = {4},
pages = {313--316},
doi = {10.1111/bdi.13435}
}
EUVIMED